I think Zenith should use their current scientists or hire professors and start teaching courses in cancer epigenetic drugs. That way they will start generating revenue. They might even develop new science.

Then, in 4 or 5 years they should hire some business profs, perhaps from Harvard, to develop an MBA program. The first assignment for the MBA students should be "to determine how to turn Zenith into a business with a focus on shareholder value".

Perhaps then, in 10 years or so, we'll receive a return on our investment.

I just couldn't help it. I just needed a moment of levity in this madness of RVX and Zenith.

Please bring in the  experienced biotech finance and business people and get on with it.

Cheers and GLTA because we need it.

Toinv   :)